1. Clinical Overview
A fixed-dose combination (FDC) of three agents for comprehensive secondary prevention of atherothrombotic events. Aspirin and Clopidogrel provide synergistic antiplatelet action (dual antiplatelet therapy - DAPT) to prevent arterial thrombosis, while Atorvastatin provides lipid-lowering and plaque-stabilizing effects. This combination is a cornerstone in the management of patients with established cardiovascular disease (CVD) to reduce the risk of recurrent myocardial infarction (MI), stroke, and cardiovascular death.
| Onset | Duration | Bioavailability |
|---|---|---|
| Aspirin: 30-60 minutes (irreversible effect); Clopidogrel: 2 hours (peak platelet inhibition in 3-7 days with repeated dosing); Atorvastatin: LDL-C reduction begins within 2 weeks. | Aspirin: 7-10 days (platelet lifespan); Clopidogrel: 5-7 days (platelet lifespan); Atorvastatin: 24 hours (requires daily dosing). | Aspirin: ~50% (rapidly hydrolyzed to salicylate); Clopidogrel: >50%; Atorvastatin: ~14% (due to extensive first-pass metabolism). |
2. Mechanism of Action
This combination exerts a multi-pronged attack on the atherothrombotic process. Aspirin irreversibly acetylates platelet cyclooxygenase-1 (COX-1), inhibiting thromboxane A2 (TXA2) synthesis, a potent platelet aggregator and vasoconstrictor. Clopidogrel is a prodrug whose active metabolite irreversibly blocks the P2Y12 subtype of ADP receptors on platelet surfaces, inhibiting ADP-mediated platelet activation and aggregation. Their effects are synergistic. Atorvastatin competitively inhibits HMG-CoA reductase, the rate-limiting enzyme in hepatic cholesterol synthesis, leading to upregulation of LDL receptors and increased clearance of LDL-C from blood. It also exerts pleiotropic effects including plaque stabilization, improved endothelial function, and anti-inflammatory actions.
3. Indications & Uses
- Secondary prevention of recurrent atherothrombotic events in patients with established Cardiovascular Disease (CVD)
- Post-Acute Coronary Syndrome (ACS: Unstable Angina, NSTEMI, STEMI) management
- Post-Percutaneous Coronary Intervention (PCI) with stent implantation (Drug-eluting or Bare-metal)
4. Dosage & Administration
Adult Dosage: One tablet (Aspirin 75mg + Atorvastatin 10mg + Clopidogrel 75mg) orally once daily. Usually taken in the evening for Atorvastatin (though timing is flexible).
Administration: Swallow the tablet whole with a glass of water, with or without food. Can be taken at any time of day, but consistency is key. Do not crush or chew. If a dose is missed, take it as soon as remembered unless it's almost time for the next dose. Do NOT double the dose.
5. Side Effects
Common side effects may include:
- Increased bleeding tendency (bruising, epistaxis, gingival bleeding)
- Dyspepsia, nausea, abdominal pain
- Headache, dizziness
- Constipation, diarrhea
- Myalgia (muscle pain) - Atorvastatin related
- Elevated liver enzymes (AST/ALT)
6. Drug Interactions
| Drug | Effect | Severity |
|---|---|---|
| Warfarin, NOACs (Apixaban, Rivaroxaban, etc.) | Profoundly increased risk of major bleeding. | Contraindicated/Severe |
| Other NSAIDs (Ibuprofen, Diclofenac) | Increased GI bleeding risk; may antagonize Aspirin's antiplatelet effect. | Major |
| Proton Pump Inhibitors (Omeprazole, Esomeprazole) | May reduce Clopidogrel's antiplatelet effect (CYP2C19 inhibition), particularly with Omeprazole/Esomeprazole. Pantoprazole is preferred. | Moderate |
| CYP3A4 Inhibitors (Ketoconazole, Itraconazole, Clarithromycin, HIV protease inhibitors) | Increase Atorvastatin exposure, raising risk of myopathy/rhabdomyolysis. | Major |
| CYP2C19 Inhibitors (Fluconazole, Fluoxetine, Citalopram) | May reduce conversion of Clopidogrel to active metabolite. | Moderate |
| Other Antiplatelets (Ticagrelor, Prasugrel) | Not used together; would be triple antiplatelet therapy with excessive bleeding risk. | Contraindicated |
| Fibrates (Gemfibrozil, Fenofibrate) | Increased risk of myopathy with Atorvastatin (Gemfibrozil risk > Fenofibrate). | Major |
| Methotrexate | Aspirin can reduce renal clearance of Methotrexate, increasing toxicity. | Major |
| SSRIs/SNRIs (Sertraline, Venlafaxine) | Additive risk of bleeding. | Moderate |
| Ginkgo Biloba, Garlic, Ginseng (Herbal) | Increased bleeding risk. | Moderate |
7. Patient Counselling
- DO take the tablet exactly as prescribed, at the same time each day.
- DO inform all your doctors and dentists about all medications you are taking, especially before any surgery or dental procedure.
- DO report any signs of unusual bleeding (blood in urine/stool, black tarry stools, prolonged nosebleeds, excessive bruising) immediately.
- DO get regular blood tests (lipid profile, LFT, CPK) as advised by your doctor.
- DONT stop taking this medicine suddenly without consulting your doctor, as it may increase risk of heart attack or stroke.
- DONT take other NSAIDs (like Ibuprofen, Diclofenac) for pain relief without consulting your doctor.
- DONT consume grapefruit juice in large quantities.
8. Toxicology & Storage
Overdose: ASPIRIN: Tinnitus, vertigo, headache, confusion, hyperventilation, fever, sweating, nausea/vomiting, metabolic acidosis, respiratory alkalosis, coma, cardiovascular collapse. CLOPIDOGREL: Bleeding complications. ATORVASTATIN: Elevated transaminases, possible severe myopathy/rhabdomyolysis.
Storage: Store in a cool, dry place, protected from light and moisture. Keep at room temperature (15-30°C). Keep out of reach of children. Do not use after the expiry date printed on the pack.